{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parkinson Study Group SURE-PD3 Investigators"],"funding":["NINDS NIH HHS"],"pagination":["926-939"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8441591"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["326(10)"],"pubmed_abstract":["<h4>Importance</h4>Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data.<h4>Objective</h4>To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression.<h4>Design, participants, and setting</h4>Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (<5.8 mg/dL) were randomized between August 2016 and D"],"journal":["JAMA"],"pubmed_title":["Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial."],"pmcid":["PMC8441591"],"funding_grant_id":["U01 NS090259","U01 NS089666"],"pubmed_authors":["Brodsky M","Waters C","Daley A","Zhang L","Goetz C","LeWitt PA","Houghton DJ","James R","LaFaver K","Hunter C","Suski V","Langhammer A","Ahmed A","Pahwa R","Bwala G","Jain S","Rezak M","Espay AJ","de Marcaida JA","Mestre T","Russell D","Shah BB","Peterson C","Leehey M","Oakes D","Poon C","Serrano C","Casaceli C","Kostrzebski M","Ascherio A","Bodis-Wollner I","Curhan GC","Houston E","Macklin EA","Goudreau J","Bolger P","Rudolph A","Bhatti D","Pothier L","Thomas K","Schneider RB","Soileau M","Mihaila D","Laroche A","Shill HA","Rabin M","Bixby M","Shoulson I","Ratel AS","Togasaki DM","Videnovic A","Waikar SS","McMahon GM","Keith K","Bluett B","Zauber SE","Kumar R","Criswell SR","Litvan I","Gauger L","Ciccarello J","Mari Z","Lang A","Mozaffarian D","Christine C","Kaminski P","Dewey RB","Deik AF","Blindauer K","Gerald A","Hauser RA","Gunzler SA","Fitzgerald R","Crotty GF","Evatt M","Fang JY","Boyd JT","Simon DK","Mehta SH","Stover N","Schwarzschild MA","Marek K","Kurlan R","Park A","Friedman JH","Reich S","Ainslie M","Aldred J","Scott B","Hung A","Durphy J","Lungu C","Beck CA","Schiess MC","Chou K","Simuni T","Mosovsky S","LeDoux MS","Jimenez-Shahed J","Rosenthal L","Cloud L","Callahan KF","Shprecher D","Henchcliffe C","Klements D","Saint-Hilaire M","Parkinson Study Group SURE-PD3 Investigators","Kamp C","Hinson V","McGraw M","Morgan JC"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.","description":"<h4>Importance</h4>Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data.<h4>Objective</h4>To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression.<h4>Design, participants, and setting</h4>Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (<5.8 mg/dL) were randomized between August 2016 and D","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-31T05:00:43.333Z","creation":"2026-04-08T08:11:38.853Z"},"accession":"S-EPMC8441591","cross_references":{"pubmed":["34519802"],"doi":["10.1001/jama.2021.10207"]}}